Adverse events
| Placebo (N=30) | Adalimumab (N=30) | |
|---|---|---|
| Adverse events | 8 | 13 |
| Patients experiencing at least one adverse event 8 | 7 | 7 |
| Infections | 4 | 2 |
| Upper respiratory tract* | 1 | 2 |
| Urinary tract* | 1 | 0 |
| Folliculitis* | 1 | 0 |
| Conjunctivitis* | 1 | 0 |
| Non-infectious events | 4 | 11 |
| Injection site reactions* | 0 | 1 |
| Weight loss | 0 | 1 |
| Weight gain | 1 | 0 |
| Vertigo | 1 | 2 |
| Angor pectoris | 1 | 0 |
| Urticaria | 0 | 1 |
| Headache | 0 | 1 |
| Pyrosis (heartburn) | 0 | 1 |
| Tendinitis | 0 | 1 |
| Hypertension | 0 | 1 |
| Erythematous cutaneous rash | 0 | 1 |
| Toxicoderma | 0 | 1 |
| Shoulder pain | 1 | 0 |
No serious adverse events or malignancies were reported; no significant differences in numbers of adverse events; adverse events marked with * may be treatment related.